Graham K. Cooper's Insider Trades & SAST Disclosures
Graham K. Cooper's most recent trade in Kezar Life Sciences Inc was a trade of 50,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 20, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Graham K. Cooper.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kezar Life Sciences Inc | Graham K. Cooper | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Beam Therapeutics Inc | Graham K. Cooper | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 23,114 | 23,114 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Graham K. Cooper | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Graham K. Cooper | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Graham K. Cooper | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 26,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Graham K. Cooper | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Graham K. Cooper | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 26,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Graham K. Cooper | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 26,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Graham K. Cooper | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 8,896 | 0 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Graham K. Cooper | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 8,896 | 8,896 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Graham K. Cooper | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 8,896 | 0 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Graham K. Cooper | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 8,896 | 8,896 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Graham K. Cooper | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Beam Therapeutics Inc | Graham K. Cooper | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 16,532 | 16,532 | - | - | Stock Option (Right to Buy) | |
| Beam Therapeutics Inc | Graham K. Cooper | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2022 | 10,391 | 10,391 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Graham K. Cooper | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 26,000 | 26,000 | - | - | Stock Option (right to buy) | |
| Kezar Life Sciences Inc | Graham K. Cooper | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2022 | 26,000 | 26,000 | - | - | Stock Option (right to buy) | |
| Applied Molecular Transpor... | Graham K. Cooper | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2022 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) | |
| Beam Therapeutics Inc | Graham K. Cooper | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.00 per share. | 06 Jul 2021 | 2,614 | 2,614 (0%) | 0% | 17 | 44,438 | Common Stock |
| Beam Therapeutics Inc | Graham K. Cooper | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jul 2021 | 2,614 | 16,561 | - | - | Stock Option (Right to Buy) | |
| Beam Therapeutics Inc | Graham K. Cooper | Director | Sale of securities on an exchange or to another person at price $ 115.38 per share. | 06 Jul 2021 | 614 | 2,000 (0%) | 0% | 115.4 | 70,843 | Common Stock |
| Beam Therapeutics Inc | Graham K. Cooper | Director | Sale of securities on an exchange or to another person at price $ 121.59 per share. | 06 Jul 2021 | 400 | 900 (0%) | 0% | 121.6 | 48,636 | Common Stock |
| Beam Therapeutics Inc | Graham K. Cooper | Director | Sale of securities on an exchange or to another person at price $ 124.31 per share. | 06 Jul 2021 | 300 | 300 (0%) | 0% | 124.3 | 37,293 | Common Stock |
| Beam Therapeutics Inc | Graham K. Cooper | Director | Sale of securities on an exchange or to another person at price $ 123.76 per share. | 06 Jul 2021 | 200 | 600 (0%) | 0% | 123.8 | 24,752 | Common Stock |
| Beam Therapeutics Inc | Graham K. Cooper | Director | Sale of securities on an exchange or to another person at price $ 120.39 per share. | 06 Jul 2021 | 200 | 1,300 (0%) | 0% | 120.4 | 24,078 | Common Stock |
| Beam Therapeutics Inc | Graham K. Cooper | Director | Sale of securities on an exchange or to another person at price $ 118.35 per share. | 06 Jul 2021 | 200 | 1,600 (0%) | 0% | 118.4 | 23,670 | Common Stock |
| Beam Therapeutics Inc | Graham K. Cooper | Director | Sale of securities on an exchange or to another person at price $ 116.41 per share. | 06 Jul 2021 | 200 | 1,800 (0%) | 0% | 116.4 | 23,282 | Common Stock |
| Beam Therapeutics Inc | Graham K. Cooper | Director | Sale of securities on an exchange or to another person at price $ 129.38 per share. | 06 Jul 2021 | 100 | 0 (0%) | 0% | 129.4 | 12,938 | Common Stock |
| Beam Therapeutics Inc | Graham K. Cooper | Director | Sale of securities on an exchange or to another person at price $ 128.67 per share. | 06 Jul 2021 | 100 | 100 (0%) | 0% | 128.7 | 12,867 | Common Stock |
| Beam Therapeutics Inc | Graham K. Cooper | Director | Sale of securities on an exchange or to another person at price $ 126.51 per share. | 06 Jul 2021 | 100 | 200 (0%) | 0% | 126.5 | 12,651 | Common Stock |
| Beam Therapeutics Inc | Graham K. Cooper | Director | Sale of securities on an exchange or to another person at price $ 122.85 per share. | 06 Jul 2021 | 100 | 800 (0%) | 0% | 122.9 | 12,285 | Common Stock |
| Beam Therapeutics Inc | Graham K. Cooper | Director | Sale of securities on an exchange or to another person at price $ 119.68 per share. | 06 Jul 2021 | 100 | 1,500 (0%) | 0% | 119.7 | 11,968 | Common Stock |
| Kezar Life Sciences Inc | Graham K. Cooper | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2021 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Beam Therapeutics Inc | Graham K. Cooper | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.00 per share. | 28 Jun 2021 | 12,045 | 12,045 (0%) | 0% | 17 | 204,765 | Common Stock |
| Beam Therapeutics Inc | Graham K. Cooper | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2021 | 12,045 | 19,175 | - | - | Stock Option (Right to Buy) | |
| Beam Therapeutics Inc | Graham K. Cooper | Director | Sale of securities on an exchange or to another person at price $ 105.37 per share. | 28 Jun 2021 | 5,787 | 6,258 (0%) | 0% | 105.4 | 609,776 | Common Stock |
| Beam Therapeutics Inc | Graham K. Cooper | Director | Sale of securities on an exchange or to another person at price $ 106.28 per share. | 28 Jun 2021 | 3,196 | 3,062 (0%) | 0% | 106.3 | 339,671 | Common Stock |
| Beam Therapeutics Inc | Graham K. Cooper | Director | Sale of securities on an exchange or to another person at price $ 107.22 per share. | 28 Jun 2021 | 1,162 | 1,900 (0%) | 0% | 107.2 | 124,590 | Common Stock |
| Beam Therapeutics Inc | Graham K. Cooper | Director | Sale of securities on an exchange or to another person at price $ 109.39 per share. | 28 Jun 2021 | 1,000 | 0 (0%) | 0% | 109.4 | 109,390 | Common Stock |
| Beam Therapeutics Inc | Graham K. Cooper | Director | Sale of securities on an exchange or to another person at price $ 108.30 per share. | 28 Jun 2021 | 900 | 1,000 (0%) | 0% | 108.3 | 97,470 | Common Stock |
| Unity Biotechnology Inc | Graham K. Cooper | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2021 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Beam Therapeutics Inc | Graham K. Cooper | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 6,877 | 6,877 | - | - | Stock Option (Right to Buy) | |
| Applied Molecular Transpor... | Graham K. Cooper | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2021 | 15,107 | 15,107 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Graham K. Cooper | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2020 | 8,896 | 8,896 | - | - | Stock Option (Right to Buy) | |
| Unity Biotechnology Inc | Graham K. Cooper | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2020 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges